A detailed history of Jpmorgan Chase & CO transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19,213 shares of JANX stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,213
Previous 19,343 0.67%
Holding current value
$1.04 Million
Previous $728,000 10.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$35.12 - $64.78 $4,565 - $8,421
-130 Reduced 0.67%
19,213 $804,000
Q1 2024

May 10, 2024

BUY
$7.93 - $49.75 $12,743 - $79,948
1,607 Added 9.06%
19,343 $728,000
Q4 2023

Feb 12, 2024

SELL
$5.85 - $11.7 $765,607 - $1.53 Million
-130,873 Reduced 88.07%
17,736 $190,000
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $46,146 - $67,578
-4,827 Reduced 3.15%
148,609 $1.5 Million
Q2 2023

Aug 11, 2023

BUY
$11.08 - $15.92 $263,471 - $378,561
23,779 Added 18.34%
153,436 $1.82 Million
Q1 2023

May 18, 2023

BUY
$11.25 - $22.21 $147,892 - $291,972
13,146 Added 11.28%
129,657 $1.57 Million
Q1 2023

May 11, 2023

BUY
$11.25 - $22.21 $143,190 - $282,688
12,728 Added 12.26%
116,511 $1.41 Million
Q4 2022

Feb 13, 2023

SELL
$11.1 - $18.26 $14,097 - $23,190
-1,270 Reduced 1.21%
103,783 $1.37 Million
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $17,041 - $26,523
1,575 Added 1.52%
105,053 $1.42 Million
Q2 2022

Aug 11, 2022

BUY
$9.52 - $15.65 $814,455 - $1.34 Million
85,552 Added 477.25%
103,478 $1.26 Million
Q1 2022

May 11, 2022

BUY
$13.24 - $20.24 $61,407 - $93,873
4,638 Added 34.9%
17,926 $256,000
Q4 2021

Feb 10, 2022

BUY
$15.44 - $27.32 $105,208 - $186,158
6,814 Added 105.25%
13,288 $262,000
Q3 2021

Nov 12, 2021

BUY
$20.7 - $34.69 $134,011 - $224,583
6,474 New
6,474 $140,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.